One more new species of Chaerilobuthus Lourenço & beigel, 2011 (Scorpiones: Chaerilobuthidae) from Early Cretaceous Burmite

Posted by
  One more new species of Chaerilobuthus Lourenço & beigel, 2011 (Scorpiones: Chaerilobuthidae) from Early Cretaceous Burmite Abstract . – The genus Chaerilobuthus is probably the most speciose group among those found in Burmite. In some recent publications most aspects concerning the family Chaerilobuthidae Lourenço & Beigel, 2011 and the genera composing it were precisely discussed; consequently, no further comments will be provided in this contribution. Only one more new species belonging to the genus Chaerilobuthus is described. Chaerilobuthus franzschmidti Lourenço sp . n ., represents the 16th species to be described for this genus confirming therefore the strong speciose characteristic of the group. The new species shows some marked morphological differences when compared to the previous known species, attesting the existence of a major variability within Chaerilobuthus . Lourenço W. R. & Velten J., 2026. – Une nouvelle espèce pour le genre Chaerilobuthus Lou...

Development of Broad-Spectrum Antiviral and Antitumor Therapeutics from Cobra Toxin (NT3) for Veterinary and Human Use

Posted by

 


Development of Broad-Spectrum Antiviral and Antitumor Therapeutics from Cobra Toxin (NT3) for Veterinary and Human Use

Abstract:

Introduction: CYGNOS BioTech is pioneering the development of broad-spectrum antiviral (PVX) and antitumor (MMX) biologic products for both veterinary and human applications. Our innovative technology has led to the issuance of nine patents covering composition, process, and usage. The US FDA has granted two Investigational New Animal Drug Applications for 1) a non-specific antiviral drug for companion animals and 2) an antitumor drug for stage II and III canine oral malignant melanoma.

Methods: PVX and MMX are derived from cobra venom toxin (NT3) through fractionation followed by proprietary chemical processes to achieve detoxification and specific biologic activities.

Results: Preliminary data suggest that PVX's antiviral activity targets host-cell mechanisms rather than the virus. PVX inhibits Protein Kinase activities, potentially affecting cellular pathways related to transcription and translation. Clinical studies in dogs, cats, and horses demonstrate significant antiviral and antitumor effects without adverse events. PVX appears effective for most viral infections, including enveloped RNA and DNA viruses such as canine distemper virus (paramyxovirus), Human and Feline Herpes viruses, and Feline Corona virus causing Feline Infectious Peritonitis (FIP).

Conclusions: The global community faces increasing threats from emerging zoonotic diseases and bio-terrorism activities. The potential for a new pandemic or the release of genetically engineered viruses is a real and devastating concern. CYGNOS BioTech’s technology serves as a potential platform to treat infectious diseases, applicable across veterinary, public health, and military sectors. The availability of a drug capable of addressing emerging and genetically engineered viruses as a first line of defense could have a profound impact.

Yourist, J.; Bogdan, J.A. Development of Broad-Spectrum Antiviral and Antitumor Therapeutics from Cobra Toxin (NT3) for Veterinary and Human Use, in Proceedings of the 3rd International Online Conference on Toxins, 10–12 September 2025, MDPI: Basel, Switzerland, https://sciforum.net/paper/view/23761